John J. Trizzino

Biography

Mr. Trizzino joined Novavax in March 2014 as the Senior Vice President, Commercial Operations with responsibility over the development and implementation of the commercialization strategy for the company’s lead product candidates: RSV, seasonal influenza and pandemic influenza vaccines. Mr. Trizzino has extensive experience in the pediatric and adult vaccine market. He previously served as Novavax’ Senior Vice President, International and Government Alliances beginning in 2009 and its Senior Vice President, Business Development from 2010 to 2011, during which he played a key role in negotiating the company’s $179 million contract with HHS BARDA. Most recently, Mr. Trizzino was the CEO of Immunovaccine, a publically traded Canadian based biotech focused on the cancer immunotherapy market. While at MedImmune, Mr. Trizzino had responsibility for trade relations and corporate accounts for Synagis, a monoclonal antibody with $1 billion in annual revenue used for the prevention of RSV in premature babies. Mr. Trizzino also had the marketing and public health sales responsibility for MedImmune’s highly differentiated nasally administered influenza vaccine FluMist. Mr. Trizzino was formerly the Senior Vice President, Business Development at ID Biomedical and Vice President, General Manager of the GIV division of Henry Schein, Inc. and then their Vice President, Business Development in the Medical Group. He received his BS from Long Island University, CW Post and his MBA from New York University, Stern School of Business. 

Research Interest

Novavax, Inc. is a clinical-stage biotechnology company committed to delivering novel products to prevent a broad range of infectious diseases. Using innovative proprietary recombinant nanoparticle vaccine technology, we produce vaccine candidates to efficiently and effectively respond to both known and emerging disease threats. Our vaccine candidates are genetically engineered three-dimensional nanostructures that incorporate recombinant proteins critical to disease pathogenesis.